by Jordana Choucair | Jan 25, 2022 | Payers
A new Willis Towers Watson study found that 86 percent of employers named worker mental health, stress, and burnout as key priorities in 2022, but 49 percent have yet to articulate a formal strategy for wellness. Only a quarter of the 322 employers surveyed have...
by Jordana Choucair | Jan 25, 2022 | Life Sciences
The FDA restricted the use of COVID-19 antibody treatments that don’t appear effective against the Omicron variant. The agency saying the decision will be in place while the strain is dominant. Some health systems stopped using the treatments weeks ago, although...
by Jordana Choucair | Jan 25, 2022 | Life Sciences
Johnson & Johnson said it expects its COVID-19 vaccine to bring in up to $3.5 billion this year, up from $2.39 billion in 2021. Still, contributions from its COVID-19 vaccine are a small percentage of the company’s total revenue because it sells its vaccine at a...
by Jordana Choucair | Jan 25, 2022 | Life Sciences
Pfizer Inc. and BioNTech SE said they are testing a version of their COVID-19 vaccine that targets the Omicron variant. Pfizer said results are expected in the first half of the year so that an Omicron-specific vaccine is available “should it be needed.”...
by Jordana Choucair | Jan 25, 2022 | Inequities and SDOH
Public Citizen is pushing Pfizer to make its COVID-19 antiviral pill more broadly available in lower-income countries to address the existing global inequities in access to vaccines and treatments. The advocacy group argued in a letter to Pfizer Chief Executive Albert...
Recent Comments